Cellectar Biosciences
CLRBCellectar Biosciences is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of targeted cancer treatments.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Cellectar Biosciences is a late-stage clinical biopharmaceutical company dedicated to the discovery and development of targeted cancer treatments. The company utilizes its proprietary Phospholipid Ether Drug Conjugate (PDC) platform to deliver therapeutic payloads, such as radioisotopes, directly to malignant cells while minimizing damage to healthy tissue. Its primary focus is advancing a pipeline of radioconjugates to address high unmet needs in rare and refractory cancers.
A late-stage clinical player with FDA Breakthrough Therapy and Orphan Drug designations for its lead radioconjugate candidate.
Questions, answered.
- What is Cellectar Biosciences's market cap?
- Cellectar Biosciences (CLRB) has a market capitalization of $19.3M and trades on NASDAQ.
- Who are Cellectar Biosciences's competitors?
- Cellectar Biosciences's key competitors include Lantheus Holdings, PLUS THERAPEUTICS, Inc. Common Stock, Corbus Pharmaceuticals Holdings, Inc., and others. These companies compete in similar markets and product categories.
- Who does Cellectar Biosciences partner with?
- Cellectar Biosciences's notable partners include National Cancer Institute, Food and Drug Administration, European Medicines Agency, and others.
- Where is Cellectar Biosciences headquartered?
- Cellectar Biosciences is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 2005.